Our company is focus on the development of tools for single-cell/single-bacteria research. We are delighted to introduce our latest innovation, a next-generation high-throughput single-cell screening platform capable of conducting hundreds of thousands of single-cell experiments within a mere 2-hour timeframe. Moreover, we have developed software that accurately predicts antibody sequences, significantly reducing the time and cost required for antibody screening and subsequent functional verification.